Guggenheim Reiterates Buy Rating on Rezolute, Inc.
Guggenheim maintains its buy rating on Rezolute, Inc. with an $11 price target, a 119.12% upside from the current price.
Key Points
- Guggenheim analyst Debjit Chattopadhyay reiterated a buy rating on Rezolute, Inc. with an $11 price target on June 15, 2026.
- Guggenheim's $11 price target implies 119.12% upside from Rezolute, Inc.'s ($RZLT) current $5.02 share price.
- Rezolute, Inc. shares are trading at $4.00 with a market cap of $416.9 million, and it operates in the biotechnology sector.
- Insiders, including CFO Daron Evans, have been active recently with both buying and selling transactions.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Guggenheim analyst Debjit Chattopadhyay has reiterated a buy rating on Rezolute, Inc. (NasdaqCM: RZLT) as of June 15, 2026. The firm maintained its price target of $11 for the biotechnology company, which is currently trading at $4.00.
Other Institutional Activity in Rezolute, Inc.
Several institutional investors have been adjusting their positions in Rezolute, Inc. Federated Hermes, Inc. reduced its holdings by 3,544,053 shares, ending with 12,990,659 shares valued at approximately $39.6 million. RA Capital Management, L.P. maintained its position with 9,180,000 shares worth about $28.0 million. BlackRock, Inc. trimmed its stake by 454,703 shares, leaving it with 6,313,503 shares valued at around $19.3 million. Meanwhile, Opaleye Management Inc. slightly increased its position by 12,844 shares to a total of 6,300,000 shares, valued at about $19.2 million. Balyasny Asset Management L.P. boosted its holdings by 541,560 shares, now holding 5,048,421 shares worth approximately $15.4 million.
Rezolute, Inc. Stock Up 8.7%
Shares of NasdaqCM: RZLT are trading around $4.00. Rezolute, Inc. has a market capitalization of approximately $416.9 million. The company has a forward P/E ratio of -6.91 and a beta of 0.65, indicating lower volatility compared to the market. The stock's 52-week low is $1.07, and its high is $11.46. It has a 50-day moving average of $3.48 and a 200-day moving average of $5.25. The company maintains a strong financial position with a current ratio of 15.84 and a quick ratio of 15.61, alongside a debt-to-equity ratio of 0.95.
Recent Earnings
Rezolute, Inc. is currently not profitable, with an EPS of -$0.81. The company has a net margin of 0.0% and a return on equity of -81.7%. Investors are looking forward to the next earnings report, scheduled for September 16, 2026.
Insider Buying and Selling at Rezolute, Inc.
Recent insider transactions include CFO Daron Evans purchasing 10,000 shares at an average price of $2.85 on March 30, 2026. CEO Nevan Elam sold 27,618 shares at $2.99 on March 2, 2026. Chief Medical Officer Brian Kenneth Roberts also sold 11,439 shares on the same day at $2.99. In earlier transactions, Roberts bought 28,000 shares at $1.70 on December 16, 2025, while Wladimir Hogenhuis purchased 5,650 shares at $1.69.
Analysts Set New Price Targets
On June 15, 2026, Guggenheim maintained its buy rating with an $11 target. Maxim Group also kept its buy rating on June 3, 2026, with a target of $14. The consensus among analysts is a buy recommendation, with a mean target price of $7.11 across nine opinions.
About Rezolute, Inc.
Rezolute, Inc. is a biotechnology company focused on treating rare diseases, particularly those related to hypoglycemia caused by hyperinsulinism. Headquartered in Redwood City, California, the company is led by CEO Nevan Charles Elam. Rezolute's key product, ersodetug, is in Phase 3 trials for treating congenital hyperinsulinism. Founded in 2010, Rezolute aims to improve outcomes for individuals with these challenging conditions.
Bottom Line
Guggenheim's reiterated buy rating on Rezolute, Inc. reflects confidence in the company's prospects. With a strong cash position and ongoing clinical trials, Rezolute remains a key player in the biotechnology sector. Investors should note that analyst ratings are based on past data and expectations, which may not reflect future performance.
Get Rezolute, Inc. alerts
New 13F filings, insider trades, and analyst moves on $RZLT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.